This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SPC865. CME/MOC/AAPA credit will be available until October 15, 2026.

Improving the Care of Patients With Hereditary Angioedema: Maximizing Protection With Long-Term Prophylaxis

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Ionis Pharmaceuticals, Inc.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/FVW865. CME/MOC/CC/AAPA credit will be available until September 28, 2026.

Navigating Biologic Therapy in CRSwNP: From Patient Selection to Response Assessment

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/SPP865. CME/AAPA credit will be available until August 4, 2026.

Collaborating With Peers to Optimize Obesity Management in Women: Clinical Considerations Before, During, and After Pregnancy

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/QPE865. CME/MOC/AAPA credit will be available until June 20, 2026.

Advancing Care for Chronic Spontaneous Urticaria: Navigating an Evolving Treatment Landscape for Optimal Patient Outcomes

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 17, 2026.

Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care?

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/AYT865. CME/MOC/CC credit will be available until November 9, 2025.

Uncovering the Role of Epithelial Cytokines in CRSwNP: Examining the Clinical Implications of New Approaches with Targeted Biologic Therapy

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from AstraZeneca LP.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NZV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until July 23, 2025.

The Itch We Could Never Scratch: Incorporating New and Emerging Therapies to Alleviate the Burden of Prurigo Nodularis With a Team-Based Approach

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/XWR865. CME credit will be available until June 4, 2025.

Aligning Clinical Practice With Emerging Evidence: Navigating the Rapidly Evolving Landscape of Glomerular Kidney Disease Management

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/RFB865. CME/MOC/AAPA credit will be available until April 8, 2025.

Advancing Patient Care in Chronic Spontaneous Urticaria: Reshaping the Future With Targeted Biologic Therapies

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/SVX865. CME/MOC/AAPA credit will be available until March 7, 2025.

Evolving Concepts in the Pathogenesis of Inflammatory Dermatologic Disorders and the Rationale for Targeted Biologic Therapy: Focus on Moderate to Severe Atopic Dermatitis, Prurigo Nodularis, Chronic Urticaria, and Bullous Pemphigoid

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Adam Friedman, MD, FAAD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Arcutis Biotherapeutics, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.
Grant/Research Support from Incyte and Janssen Pharmaceuticals, Inc.
Speaker for Bristol Myers Squibb; Incyte; Janssen Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals Inc./Sanofi.

Co-Chair/Planner
Shawn Kwatra, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcutis Biotherapeutics, Inc.; Asian Pharmaceuticals Pvt. Ltd.; Bristol Myers Squibb; Cara Therapeutics; Castle Biosciences, Inc.; Celldex Therapeutics; Dermavant Sciences, Inc.; Galderma; Genzada Pharmaceuticals USA, Inc.; Incyte; Johnson & Johnson Services, Inc.; LEO Pharma A/S; Novartis Pharmaceuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.
Grant/Research Support from Galderma; Incyte; Pfizer; and Sanofi.

Co-Chair/Planner
Peter A. Lio, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Almirall, S.A.; Amyris, Inc.; AOBiome; ASLAN Pharmaceuticals Pte Ltd; Bristol Myers Squibb; Burt’s Bees Products Company; Concerto Biosciences; Dermavant Sciences, Inc.; Galderma S.A.; Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Merck & Co., Inc.; Micreos B.V.; MyOR; Pfizer; Pierre Fabre group; Regeneron Pharmaceuticals Inc./Sanofi Genzyme; Theraplex; UCB, Inc.; and Verrica Pharmaceuticals.
Grant/Research Support from AbbVie Inc. and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.
Speakers Bureau participant with AbbVie Inc.; Galderma S.A.; Incyte; Leo Pharma Inc.; Lilly; L’Oréal USA, Inc.; Pfizer; and Regeneron Pharmaceuticals Inc./Sanofi Genzyme.

Co-Chair/Planner
Professor Dedee Murrell has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amryt Pharma plc; Castle Creek Biosciences, Inc.; Krystal Biotech; and RHEACELL GmbH & Co. KG.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/MPM865. CME/MOC/NCPD/AAPA credit will be available until February 6, 2025.

Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Co-Chair/Planner
Erin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
David Rosmarin, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.
Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Go online to PeerView.com/DRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Atopic dermatitis (AD) carries a significant disease burden, and evidence shows there is often a mismatch in perception of disease severity between patients and their providers. Further, the treatment landscape is complex, with multiple approved therapies, including targeted biologic agents, which have revitalized treatment of the disease. Along with patient vignettes and a 3D-animated video clip, this activity features AD experts discussing the assessment of severity in AD, the underlying pathophysiology of AD, and the role of targeted therapy in reducing AD flares and achieving and maintaining control of the disease. Upon completion of this activity, participants should be better able to: Recognize the significant burden of moderate to severe atopic dermatitis (AD) on patients, including the impact of itch, depression, sleep disturbance, anxiety, and treatment dissatisfaction; Describe underlying mechanisms, including immunological and epidermal barrier dysfunction, that contribute to the development of AD and provide rationale for the use of targeted biologic therapy; and Select treatment for patients with moderate to severe AD, including biologic agents as appropriate, according to recent clinical evidence and current guidelines, with a goal of minimizing/preventing flares.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPZ865. CME credit will be available until December 21, 2024.

Optimizing Real-World Outcomes in Wet AMD: Reducing the Burden of Treatment With Longer-Acting Therapies

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Rishi P. Singh, MD, FASRS, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alcon; Apellis Pharmaceuticals; Bausch & Lomb Incorporated; Genentech, Inc.; IVERIC bio, Inc., An Astellas Company; Novartis/Gyroscope; and Regeneron Pharmaceuticals Inc.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/FHQ865. CME credit will be available until December 15, 2024.

Retinal Disease in the ED: “See Me Now”- A Primer for Emergency Physicians on the Recognition and Differential Diagnosis of Retinal Vein Occlusions

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Emergency Physicians and PVI, PeerView Institute for Medical Education. The American College of Emergency Physicians is accredited by the ACCME to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Disclosures
Robert M. Hughes, DO, has no financial interests/relationships or affiliations in relation to this activity.

Christina Y. Weng, MD, MBA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Alcon; Allergan/AbbVie Inc.; Alimera Sciences; Apellis Pharmaceuticals; Dutch Ophthalmic Research Center (DORC); EyePoint Pharmaceuticals, Inc.; Genentech, Inc.; IVERIC bio, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and REGENXBIO.
Grant/Research Support from AGTC; Alimera Sciences; and DRCR Retina Network.
Other Financial or Material Support in the form of royalties from Springer Publishers.

Medical Director
Kristin Tomlinson, PhD, has no financial interests/relationships or affiliations in relation to this activity.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/UKS865. CME/MOC/AAPA credit will be available until November 13, 2024.

Facing the Challenges of EoE Head On: A Game Plan for Diagnosis and Integrating Targeted Therapy Using a Team Approach

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Dan Atkins, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for The American Partnership for Eosinophilic Disorders (APFED) and CURED.

Patient/Planner
Valira Pietrangelo has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZTQ865. CME/MOC/AAPA credit will be available until November 8, 2024.

Clearing the Way for Pediatric Patients of All Races With Moderate to Severe Atopic Dermatitis: Expert Perspectives on Identifying and Assessing Disease Severity and Implementing Targeted Treatment

Atopic dermatitis (AD) is a chronic disease that affects a large proportion of the US population and is associated with a heavy disease burden that affects patients and their families. Topical treatment options for AD have limitations related to efficacy, tolerability, and safety concerns but the availability of biologic agents for both pediatric and adult patients with AD has revitalized the treatment landscape for this chronic disease. However, challenges remain with the identification and assessment of severity of AD, particularly with regard to age- and race-related differences in AD features, and with utilizing targeted therapy appropriately, especially in pediatric patients. This activity will provide learners with expert guidance regarding the identification and assessment of AD severity in children and practical strategies regarding the integration of targeted biologic therapy for pediatric patients with moderate to severe AD.

Chair
Amy S. Paller, MD
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Patient Advocate
Kacey Jenkins


In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and National Eczema Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Disclosure Policy
PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures
Chair/Planner
Amy S. Paller, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Abeona Therapeutics Inc.; Aegerion Pharmaceuticals Inc.; Azitra; BioCryst Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Castle Creek Biosciences, Inc.; Catawba Research, LLC; Galderma S.A.; InMed Pharmaceuticals, Inc.; Johnson and Johnson Services, Inc.; Krystal Biotech, Inc.; Leo Pharma Inc.; Lilly; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; SanofiGenzyme; TWi Biotechnology, Inc.; and UCB, Inc.
Grant/Research Support from Castle Creek Biosciences, Inc.; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Krystal Biotech, Inc; Lilly; Regeneron Pharmaceuticals Inc.; and UCB, Inc.


Patient Advocate/Planner
Kacey Jenkins has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Go online to PeerView.com/RBD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated video activity, Dr. Stanley C. Jordan discusses the rationale for targeting IL-6 in chronic active antibody-mediated rejection, as well as the use of anti–IL-6 agents for the treatment of chronic active antibody-mediated rejection in the kidney transplant setting. Upon completion of this activity, participants should be better able to: Utilize the Banff classification to characterize the nature and extent of kidney transplant rejection in order to guide treatment; Discuss the rationale for targeting IL-6 as a therapeutic approach to chronic active antibody-mediated rejection in kidney transplant recipients; and Evaluate the efficacy, safety, and clinical potential of anti–IL-6 agents currently in development for the treatment of chronic active antibody-mediated rejection in the kidney transplant setting

Go online to PeerView.com/CDT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Prurigo nodularis (PN) is a chronic inflammatory skin condition marked by intensely pruritic, hyperkeratotic nodules distributed on the trunk and extremities. Severe itching contributes to scratching, bleeding, thickening of nodules, and scarring. PN can significantly reduce quality of life, affect sleep and mental health, and hamper participation in activities of daily living and social interaction. Until recently, there were no approved treatments for PN, but one agent has been granted a PN indication, and others are in late-stage development. In this activity, based on a recent live symposium, a panel of experts offers personal guidance on the pathophysiology, burden, and new and promising treatment options for PN. The discussion is enhanced by 3D animation depicting PN pathophysiology plus patient videos that provide compelling perspectives on the burdens of the disease and the experience of treatment. Upon completion of this activity, participants should be better able to: Discuss the burden of disease and unmet needs experienced by patients with prurigo nodularis (PN); Explain how a growing understanding of PN pathophysiology has contributed to the development of novel therapeutic strategies; and Develop individualized treatment plans for PN in accordance with current evidence and expert recommendations using current and emerging treatment options as they become available.

Go online to PeerView.com/RJF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hidradenitis suppurativa (HS) is a chronic, inflammatory dermatologic condition characterized by the occurrence of suppurative, painful lesions, typically in the intertriginous areas. Diagnostic delay is common and is correlated with an increase in disease severity and a decrease in quality of life. While existing treatments are often inadequate and do not help all patients, one biologic agent is approved for the management of HS and a number of other emerging agents are currently undergoing phase 2 and 3 trials. In this activity, experts in dermatology will review symptomatology and provide strategies for making a timely and accurate diagnosis of HS and will offer practical guidance on incorporating existing and emerging therapies into the management of HS, with an emphasis on quality-of-life considerations. Upon completion of this activity, participants should be better able to: Identify signs, symptoms, and diagnostic challenges to make a timely and accurate diagnosis of hidradenitis suppurativa; Describe the burdens of disease and impact on quality of life for patients with hidradenitis suppurativa; Recognize the limitations of current therapies for hidradenitis suppurativa; and Apply clinical safety and efficacy data on emerging novel treatments for patients with hidradenitis suppurativa

Go online to PeerView.com/QYD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the choice of regimens for patients with hepatocellular carcinoma (HCC) continues to expand with new standard-of-care therapies for advanced disease, and emerging innovative locoregional and multimodal strategies for early- and intermediate-stage disease, clinicians who treat liver cancer have increased opportunities to collaborate with colleagues and improve patient outcomes. Designed to guide professionals into a new era of team-based personalized care, this Seminars & Tumor Board activity features a multidisciplinary panel of experts who will link current science and treatment recommendations to practical guidance on therapeutic decision-making. Using case-based discussion, the expert panel will address a variety of clinical issues such as treatment selection, sequencing, and the integration of systemic therapy with locoregional management. It takes a team to provide the best care for your patients—participate in this activity to hear the latest on using collaborative strategies to optimize outcomes in HCC. Upon completion of this activity, participants should be better able to: Evaluate the efficacy/safety profiles and clinical roles of novel and emerging systemic therapy approaches for patients with advanced/metastatic HCC; Review the latest evidence on innovative strategies, including novel locoregional modalities, combinations of locoregional and systemic therapies, and perioperative/conversion approaches, for patients with HCC across the disease continuum; Develop contemporary, personalized management plans for patients with HCC that consider the available clinical evidence, expert/guideline recommendations, clinical trial opportunities, and patient-, disease-, and treatment-specific factors; and Implement best practices for multidisciplinary collaboration and care coordination when managing patients with HCC, including team-based strategies to maximize treatment efficacy, safety, tolerability, and patient quality of life.